<div id="readability-page-1"><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks </li></ul>GRI Bio ( (GRI) ) has issued an announcement. On May 14, 2026, GRI Bio reported first-quarter 2026 results and new Phase 2a data showing its IPF candidate GRI-0621 improved key clinical symptoms and safety measures when added to standard-of-care antifibrotics. In 35 idiopathic pulmonary fibrosis patients, the once-daily oral drug was associated with zero cough in the active arm, reduced dyspnea, no weight loss and roughly 60% lower treatment-related diarrhea than placebo, despite higher nintedanib use, and showed no serious adverse events. Exploratory analyses indicated improvements in lung function and biomarker evidence of immune rebalancing, anti-fibrotic activity and epithelial repair, supporting GRI-0621’s differentiated profile and underpinning new patent filings. Financially, the company ended March 31, 2026, with $11.0 million in cash after raising $6.8 million through its ATM facility, narrowed its quarterly net loss to $2.0 million as R&amp;D spending fell following completion of the Phase 2a trial, and said existing resources should fund operations into the second quarter of 2027 while it advances GRI-0621 toward pivotal development and progresses autoimmune candidate GRI-0803 toward IND-enabling work. The most recent analyst rating on (GRI) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on GRI Bio stock, see the GRI Stock Forecast page. Spark’s Take on GRI Stock According to Spark, TipRanks’ AI Analyst, GRI is a Neutral. The score is held down primarily by weak financial performance (widening losses, negative margins, and elevated cash burn) and bearish technicals (below key moving averages with negative MACD). A low-debt balance sheet and encouraging Phase 2a updates provide partial offsets, but the negative P/E and lack of dividend support keep the overall profile risk-tilted. To see Spark’s full report on GRI stock, click here. More about GRI Bio GRI Bio, Inc. is a clinical-stage biopharmaceutical company developing therapies that modulate Natural Killer T cells to treat inflammatory, fibrotic and autoimmune diseases. Its lead candidate, GRI-0621, is an oral RARβ/γ-selective agonist in development for idiopathic pulmonary fibrosis, and the company is also advancing a pipeline of type 2 diverse NKT agonists for autoimmune indications such as systemic lupus erythematosus. With a proprietary library of more than 500 compounds, GRI Bio aims to build a broad portfolio of immune-modulating drugs targeting early points in the inflammatory cascade. The company’s strategy focuses on disease modification by rebalancing immune responses, promoting fibrolysis and tissue repair in conditions with significant unmet medical need. Average Trading Volume: 85,374 Technical Sentiment Signal: Sell Current Market Cap: $3.29M </div>

LABU

SBIO

LABD

GRI Bio reported promising Phase 2a data for its IPF candidate GRI-0621, showing significant improvements in clinical symptoms and safety compared to standard antifibrotics. The company ended Q1 2026 with $11 million in cash and narrowed its net loss to $2 million. Analysts rate GRI stock as a Buy with a $10 target, though concerns about financial performance and technical indicators persist. GRI Bio focuses on therapies for inflammatory and autoimmune diseases, with a pipeline aimed at immune modulation.

GRI Bio Highlights Promising Phase 2a IPF Data, Outlook